MedTrace Logo

Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease

NCT01363336 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1882

Last updated 2015-04-06

No results posted yet for this study

Summary

This study is a post-marketing surveillance in Japan, and it is a local prospective, company sponsored and observational study of patient who have been treated by Adalat CR for hypertension with diabetes and/or chronic kidney disease. The objective of this study is to assess safety and efficacy profile of using Adalat CR in real clinical practice. A total 2,000 patients will be recruited and be observed for 6 months. Then, patient of whom microalbumin urea and serum creatinine are continuously monitored are additionally followed for 6 months.

Conditions

Interventions

DRUG

Nifedipine (Adalat CR, BAYA1040)

patients who are administrated with Adalat CR for hypertension

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2013-06-30
Completion
2013-07-31

Countries

  • Japan

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01363336 on ClinicalTrials.gov